Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Age-male-albumin-bilirubin-platelet score stratifies hepatocellular carcinoma risk after sustained virological response in hepatitis C-related compensated advanced chronic liver disease
Sirajuk Khongviwatsathien, Tawesak Tanwandee, Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Author contributions: Khongviwatsathien S and Tanwandee T designed the study; Khongviwatsathien S performed the retrospective data collection, data verification, statistical analysis, interpretation of the results, preparation of the tables and figures, and drafted the manuscript; Tanwandee T supervised the hepatitis clinic cohort, verified the clinical data, supervised the study, contributed to the data analysis and interpretation, critically revised the manuscript for important intellectual content, and approved the final version; Both authors reviewed and approved the final manuscript and agreed to be accountable for all aspects of the work.
AI contribution statement: No artificial intelligence tools were used in the preparation of this manuscript.
Institutional review board statement: This study was reviewed and approved by the Siriraj Institutional Review Board, Faculty of Medicine Siriraj Hospital, Mahidol University (Certificate of Approval No. Si 034/2024).
Informed consent statement: Owing to the retrospective nature of the study, the requirement for obtaining written informed consent was waived by the Siriraj Institutional Review Board.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
Data sharing statement: The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request. No additional data are available.
Corresponding author: Tawesak Tanwandee, MD, Professor, Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wan
Received: June 17, 2026
Revised: July 9, 2026
Accepted: July 27, 2026
Published online: August 27, 2026
Processing time: 63 Days and 12 Hours
Revised: July 9, 2026
Accepted: July 27, 2026
Published online: August 27, 2026
Processing time: 63 Days and 12 Hours
Core Tip
Core Tip: This retrospective cohort study evaluated the age-male-albumin-bilirubin-platelet (aMAP) score for predicting hepatocellular carcinoma (HCC) risk after sustained virological response in patients with hepatitis C virus-related compensated advanced chronic liver disease. Among 571 patients followed for a median of 4.59 years, 78 developed HCC. The aMAP score outperformed other noninvasive scoring systems, and an exploratory threshold of < 55 identified 18.6% of patients with no observed HCC events. These findings suggest that the aMAP score may support individualized surveillance intensity; however, the threshold requires external validation before routine clinical implementation.